Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Inventory (2016 - 2025)

Gsk has reported Inventory over the past 10 years, most recently at $7.9 billion for Q4 2025.

  • Quarterly results put Inventory at $7.9 billion for Q4 2025, up 8.3% from a year ago — trailing twelve months through Dec 2025 was $7.9 billion (up 8.3% YoY), and the annual figure for FY2025 was $7.9 billion, up 8.3%.
  • Inventory for Q4 2025 was $7.9 billion at Gsk, up from $7.3 billion in the prior quarter.
  • Over the last five years, Inventory for GLAXF hit a ceiling of $7.9 billion in Q4 2025 and a floor of $6.0 billion in Q4 2022.
  • Median Inventory over the past 5 years was $7.3 billion (2024), compared with a mean of $7.2 billion.
  • Biggest five-year swings in Inventory: dropped 22.57% in 2022 and later grew 13.05% in 2023.
  • Gsk's Inventory stood at $7.8 billion in 2021, then dropped by 22.57% to $6.0 billion in 2022, then grew by 13.05% to $6.8 billion in 2023, then increased by 6.63% to $7.3 billion in 2024, then increased by 8.3% to $7.9 billion in 2025.
  • The last three reported values for Inventory were $7.9 billion (Q4 2025), $7.3 billion (Q4 2024), and $6.8 billion (Q4 2023) per Business Quant data.